Advanced results of Fortelyzin® use in the FRIDOM1 study and real clinical practice

Aim. To study the effectiveness of Fortelyzin® in subgroups with different body weights in patients with ST-segment elevation acute myocardial infarction (STEMI) in the FRIDOM1 study and real clinical practice.

Material and methods. Fortelyzin® was administered in a single-bolus dose of 15 mg over 10 seconds, regardless of the body weight of patients. Metalyse® was administered in a single-bolus dose of 30-50 mg over 10 seconds, depending on body weight. The one-year results of the FRIDOM1 study were evaluated by the clinical centers using telephone contact. Monitoring of Fortelyzin® use was carried out by inpatient physicians, emergency doctors and paramedics by filling out a monitoring sheet in the period from June 2013 to December 2021 in 19243 patients with STEMI.

Results. In the FRIDOM1 study, the distribution of patients depending on body weight in the Fortelyzin® (n=190) and Metalyse® (n=191) drug groups was as follows: up to 60 kg — 4 people each (p=1,00); from 60 to 70 kg — 21 and 23 (p=0,87); from 70 to 80 kg — 39 and 43 (p=0,71), from 80 to 90 kg — 63 and 47 (p=0,07); from 90 to 100 kg — 30 and 41 (p=0,19); over 100 kg — 33 people (p=1,00) in each group. The effectiveness of thrombolysis according to electrocardiographic (ECG) data in the Fortelyzin® and Metalyse® groups was as follows: up to 60 kg — 75% each (p=1,00); from 60 to 70 kg — 76% vs 83% (p=0,72); from 70 to 80 kg — 82% vs 86% (p=0,76); from 80 to 90 kg — 81% vs 77% (p=0,64); from 90 to 100 kg — 80% vs 81% (p=1,00); over 100 kg — 79% vs 76% (p=1,00); in total — 80% vs 80% (p=0,87). The effectiveness of thrombolysis according to coronary angiography (CAG) (TIMI 2-3) in the Fortelyzin® and Metalyse® groups was as follows: up to 60 kg — 100% vs 50% (p=0,43); from 60 to 70 kg — 81% vs 67% (p=0,48); from 70 to 80 kg — 74% vs 84% (p=0,41); from 80 to 90 kg — 70% vs 72% (p=1,00); from 90 to 100 kg — 67% vs 66% (p=1,00); over 100 kg — 58% vs 64% (p=0,80); in total — 70% vs 71% (p=0,76). The one-year survival rate in the FRIDOM1 study in the Fortelyzin® and Metalyse® groups was 94% (p=0,91). The administration of Fortelyzin® in patients with STEMI caused blood flow restoration according to ECG data in 14624 of 19243 patients (76%), while according to CAG (TIMI 2-3) — in 3422 of 4805 patients (71%). Inhospital mortality was 5% (n=962), while intracranial hemorrhage developed in 0,5% (n=92).

Conclusion. The use of Fortelyzin® in the FRIDOM1 study and in real clinical practice in a single-bolus (10 sec) dose of 15 mg in patients with STEMI with any body weight showed its high efficacy and safety, including at the prehospital stage.

1. The task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European society of cardiology (ESC) 2017 ESC guidelines for the management of acutemyocardial infarction in patients presenting with ST-segment elevation. Russian Journal of Cardiology. 2018;(5):103-58. (In Russ.) doi:10.15829/1560-4071-2018-5-103-158.

2. Staroverov II, Shakhnovich RM, Gilyarov MYu, et al. Eurasian clinical guidelines on diagnosis and treatment of acute coronary syndrome with ST segment elevation (STEMI). Eurasian heart journal. 2020;(1):4-77. (In Russ.) doi:10.38109/2225-1685-2020-1-4-77.

3. Russian Society of Cardiology. 2020 Clinical practice guidelines for Acute ST-segment elevation myocardial infarction. Russian Journal of Cardiology. 2020;25(11):4103. (In Russ.) doi:10.15829/29/15604071-2020-4103.

4. Morrison LJ, Verbeek PR, McDonald AC, et al. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. JAMA. 2000;283:2686-892.

5. Collen D. Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent. Nat Med. 1998;4:279-84. doi:10.1038/nm0398-279.

6. Markin SS, Semenov AM, Arzamascev EV, et al. Fortelizyn in patients with acute myocar- dial infarction. Medical Academic Journal. 2012;12(1):80-6. (In Russ.)

7. Vanderschueren S, Dens J, Kerdsinchai P, et al. Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. Am Heart J. 1997;134:213-9.

8. Markin SS, Semenov AM, Markov VA, et al. Clinical trial of fibrinselective thrombolytic pharmaceutical agent FORTELYZIN (III Phase). Rudn J Med. 2012;(1):105-10. (In Russ.)

9. Markov VA, Duplyakov DV, Konstantinov SL, et al. Fortelyzin® versus Metalyse® in ST-segment elevation myocardial infarction: results of multicenter randomized trial FRIDOM 1, Kardiologicheskij Vestnik. 2017;12(3):52-9. (In Russ.)

10. Markov VA, Duplyakov DV, Konstantinov SL, et al. Fortelyzin® in comparison with Metalyse® for ST-elevated myocardial infarction: one-year results and clinical outcomes of a multicenter randomized study FRIDOM1. Russian Journal of Cardiology. 2018;(11):110-6. (In Russ.) doi:10.15829/1560-4071-2018-11-110-116.

11. Vatutin NT, Kostogryz VB, Kostogryz AI, et al. Effectiveness of thrombolysis by nonimmunogenic staphylokinase in patient with ST-elevation myocardial infarction. Russian Journal of Cardiology. 2016;(10):105-6. (In Russ.)

12. Vatutin NT, Kostogryz VB, Stolika OI. Efficacy of the thrombolytic drug Fortelizin® in patients with acute myocardial infarction with ST segment elevation. In the collection: Donetsk readings 2016. Education, science and modern challenges. Materials of the I International Scientific Conference. 2016. pp. 292-293. (In Russ.)

13. Kireev KA, Krasnopeev AV. Our experience of hospital thrombolytic therapy for acute myocardial infarction with ST-segment elevation in a regional vascular center. Siberian Scientific Medical Journal. 2016;36(2):74-8. (In Russ.)

14. Alekseeva YaV, Vyshlov EV, Markov VA. Recombinant nonximmunogenic staphylokinase in the treatment of patients with acute myocardial infarction. The Siberian Journal of Clinical and Experimental Medicine. 2016;31(2):51-4. (In Russ.)

15. Khripun AV, Malevanny MV, Kulikovskikh YaV, Kastanayan AA. In-patient outcomes of pharmacoinvasive reperfusion strategy for ST elevation. Rus J Cardiol. 2016;(3):99104. (In Russ.) Хрипун А. В., Малеванный М. В., Куликовских Я. В., Кастанаян А. А. Госпитальные результаты фармако-инвазивной стратегии реперфузии в лечении пациентов с острым инфарктом миокарда и подъемом сегмента ST. Российский кардиологический журнал. 2016;(3):99-104.

16. Kostogryz VB. Results of Hospital Use of Recombinant Non-Immunogenic Staphylokinase in Patients with ST-Elevated Myocardial Infarction. Rational Pharmacotherapy in Cardiology. 2017;13(1):51-4. (In Russ.)

17. Rebrov BA, Bludova NG, Volkov ES, Rebrova OA. Experience of application of thrombolytic preparation fortelysin in the treatment of acute myocardial infarction. University Clinic scientific practical journal. 2017;(4-1):164-7. (In Russ.)

18. Sudakova OA, Malygin AS, Maksimenko SA, Varpetyan EE. Pharmacoeconomical analysis of the use of Fortelizin in acute myocardial infarction. Tver Medical Journal. 2017;(1):4850. (In Russ.)

19. Vishlov EV, Alekseeva YaV, Gerasimets EA, Markov VA. Experimental and clinical studies of staphylokinase and Fortelyzin®. Kardiologija. 2017;2:57-61. (In Russ.)

20. Fedorov AV, Belova LP. The principles of organization of aid and pre-hospital thrombolysis patients with acute coronary syndrome in the Chuvash Republic. Emergency medical care. 2017;18(3):39-43. (In Russ.)

21. Mazur ES, Rabinovich RM, Mazur VV, et al. Comparative Results of Recombinant Non-Immunogenic Staphylokinase and Tenecteplase Use in ST-Segment Elevation Myocardial Infarction in Real Clinical Practice. Rational Pharmacotherapy in Cardiology. 2017;13(4):463-8. (In Russ.) doi:10.20996/1819-6446-2017-13-4-463-468.

22. Khripun AV, Kastanayan AA, Malevannyi MV, Kulikovskikh YaV. The short-term outcomes of pharmaco-invasive reperfusion strategy in STEMI depending on the choice of throm bolytic drug. Emergency Cardiology. 2018;(3):12-22. (In Russ.) doi:10.25679/EMERGCARDIOLOGY.2019.94..3..002.

23. Yunevich DS, Aksentiev SB. To the question of efficacy and safety of Fortelyzin® therapy on acute coronary syndrome: two clinical cases. Eurasian heart journal. 2018;(1):82-9. (In Russ.)

24. Klein GV, Chukseev SE, Nikolaev MA, Timofeev AA. Prolonged Successful Cardiopulmonary Resuscitation with Thrombolysis in a Patient with Acute Coronary Syndrome. Rational Pharmacotherapy in Cardiology. 2018;14(6):864-9. (In Russ.)

25. Khripun AV, Kastanayan AA, Malevannyi MV, Kulikovskikh YaV. Long-Term Outcomes of Pharmacoinvasive Reperfusion Strategy Depending on the Choice of Thrombolytic Agent in ST-Segment Elevation Myocardial Infarction. Rational Pharmacotherapy in Cardiology. 2019;15(2):180-90 (In Russ.) doi:10.20996/1819-6446-2019-15-2-180-190.

26. Gorbacheva SM, Antipina LG, Gorbachev VI. Some legal issues of thrombolytics Fortelizin® n the Russian Federation in acute coronary syndromes. “Emergency Doctor”. 2017;(4). (In Russ.)

27. Gusev EI, Martynov MYu, Nikonov AA, et al. the FRIDA Study Group. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4•5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial. The Lancet Neurology. 2021;20(9):721-8. doi:10.1016/s1474-4422(21)00210-6.